Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of WSD0922-FU Plus Osimertinib in EGFR-Mutant NSCLC
ChiCTR2500108653Phase 2Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of WSD-0922 and osimertinib in Non-small cell lung cancer adenocarcinoma (NSCLC) (4 arms), sponsored by Shanghai East Hospital. Primary endpoints: Maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and dose-limiting toxicity (DLT) and Objective response rate (ORR) by RECIST 1.1. Started Aug 2025; status: recruiting.
02
Drugs
WSD-0922osimertinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500108653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108653.